JAMA Deputy Editor Mary McDermott, MD, and JAMA Deputy Editor Kristin Walter, MD, MS, highlight their selections of top JAMA 2024 Clinical Reviews podcasts. Related Content:
Chronic kidney disease develops among 30% to 40% of people with type 1 or type 2 diabetes during their lifetime. Author Ian H. de Boer, MD, MS, of the University of Washington Division of Nephrology, discusses the evaluation and treatment of chronic kidney disease in patients with type 1 and type 2 diabetes with JAMA Senior Editor Karen Lasser, MD, MPH. Related Content:
The number of people living with atrial fibrillation (AF) is increasing, and they have a higher rate of cardiovascular events, chronic kidney disease, and dementia compared with people without AF. Emelia J. Benjamin, MD, ScM, an epidemiologist and cardiologist, discusses current diagnosis and treatment of AF with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content:
Allogeneic stem cell transplantation is a potentially life-saving therapy for some patients with hematologic and bone marrow cancers and certain nonmalignant conditions such as sickle cell disease. Hermioni L. Amonoo, MD, MPP, MPH, of Harvard Medical School and Dana-Farber Cancer Institute, joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the process of allogeneic stem cell donation. Related Content:
JAMA Senior Editor Derek Angus, MD, MPH, and JAMA Associate Editor Christopher Seymour, MD, MSc, discuss 4 critical care trials published in JAMA and simultaneously presented at the 2024 CCR Down Under meeting in Melbourne, Australia, with JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS. Related Content:
Access to obstetric care in US hospitals has been declining, while maternal mortality is on the rise. A new research letter published in JAMA quantifies losses and gains of obstetric care at rural and urban short-term acute care hospitals in the US between 2010-2022. Author Katy Kozhimannil, PhD, MPA, discusses this and more with JAMA Deputy Editor Linda Brubaker, MD, MS. Related Content:
Ovarian aging is an important cause of infertility in women older than 35 years. Success rates of fertility treatment decline with age, most commonly due to declining ovarian function. Author Albert L. Hsu, MD, MS, of University of Cincinnati, Ohio, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content:
Mpox is an evolving global health threat, and clinicians should be aware of characteristic signs and symptoms to ensure timely diagnosis and appropriate management. Author Jason Zucker, MD, MS, of Columbia University Irving Medical Center speaks with JAMA Deputy Editor Preeti Malani, MD, MSJ, about the transmission, diagnosis, management, and prevention of mpox. Related Content:
Calcific aortic stenosis affects approximately 12% of people >75 years in the US and worldwide leads to more than 100 000 deaths each year. Catherine M. Otto, MD, PhD, of the University of Washington School of Medicine, Seattle, discusses the symptoms, diagnosis, and treatment of aortic stenosis with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content:
CAR T cells are genetically engineered to express a receptor that recognizes and kills tumor cells. CAR T-cell products are now FDA approved for 6 hematologic malignancies. Author Jennifer N. Brudno, MD, National Cancer Institute, joins JAMA Deputy Editor Mary McGrae McDermott, MD, to discuss "CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.” Related Content:
Peptic ulcer disease affects approximately 1% of the population in the US, and H pylori is a common cause of peptic ulcer disease. Author Nimish Vakil, MD, a gastroenterologist from the University of Wisconsin, Madison, discusses current evidence regarding diagnosis and treatment of peptic ulcer disease with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content:
Your feedback is valuable to us. Should you encounter any bugs, glitches, lack of functionality or other problems, please email us on [email protected] or join Moon.FM Telegram Group where you can talk directly to the dev team who are happy to answer any queries.